Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111839 · ClinicalTrials.gov registry record · Phase 2
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00111839 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 150 participants.
The verdict
NCT00111839, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy treatment, called pemetrexed.
Interventions
- DRUG Pemetrexed
- DRUG Matuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-05-31 |
| Est. Completion | 2009-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111839
The ClinicalTrials.gov registry entry for NCT00111839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00111839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111839 about?
NCT00111839 is a clinical study titled "Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer". This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy ...
What is the current status of trial NCT00111839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-05-31. Estimated completion is 2009-03-31.
What interventions are being tested in trial NCT00111839?
The interventions under investigation include: Pemetrexed (DRUG), Matuzumab (DRUG).
Who is sponsoring clinical trial NCT00111839?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.